Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-270
24/06/2024 12:01
June 24 (Reuters) - Adicet Bio Inc ACET.O :
* ADICET BIO ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR
ADI-270 IN RENAL CELL CARCINOMA
* ADICET BIO INC - PHASE 1 CLINICAL STUDY TO BE INITIATED IN
2H
2024; PRELIMINARY CLINICAL DATA EXPECTED IN 1H 2025
* ADICET BIO INC - PHASE 1 CLINICAL STUDY TO EVALUATE SAFETY
AND
ANTI-TUMOR ACTIVITY OF ADI-270 IN RELAPSED/REFRACTORY RCC
PATIENTS
Source text for Eikon: ID:nBw1TgLJpa
Further company coverage: ACET.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary